Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Omeros Corporation stock | $6.32

Learn how to easily invest in Omeros Corporation stock.

Omeros Corporation is a biotechnology business based in the US. Omeros Corporation shares (OMER) are listed on the NASDAQ and all prices are listed in US Dollars. Omeros Corporation employs 277 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Omeros Corporation

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – OMER – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Omeros Corporation stock price (NASDAQ: OMER)

Use our graph to track the performance of OMER stocks over time.

Omeros Corporation shares at a glance

Information last updated 2021-10-24.
Latest market close$6.32
52-week range$5.45 - $23.14
50-day moving average $11.43
200-day moving average $14.81
Wall St. target price$35.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.28

Buy Omeros Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Omeros Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Omeros Corporation price performance over time

Historical closes compared with the close of $6.32 from 2021-10-25

1 week (2021-10-20) -1.25%
1 month (2021-09-27) -56.50%
3 months (2021-07-27) -55.80%
6 months (2021-04-27) -64.99%
1 year (2020-10-26) -38.16%
2 years (2019-10-25) -60.33%
3 years (2018-10-26) 16.16
5 years (2016-10-26) 8.16

Omeros Corporation financials

Revenue TTM $86.6 million
Gross profit TTM $6.2 million
Return on assets TTM -65.87%
Return on equity TTM 0%
Profit margin -160.93%
Book value $-2.65
Market capitalisation $405.6 million

TTM: trailing 12 months

Shorting Omeros Corporation shares

There are currently 9.9 million Omeros Corporation shares held short by investors – that's known as Omeros Corporation's "short interest". This figure is 4.9% down from 10.4 million last month.

There are a few different ways that this level of interest in shorting Omeros Corporation shares can be evaluated.

Omeros Corporation's "short interest ratio" (SIR)

Omeros Corporation's "short interest ratio" (SIR) is the quantity of Omeros Corporation shares currently shorted divided by the average quantity of Omeros Corporation shares traded daily (recently around 470809.38989514). Omeros Corporation's SIR currently stands at 20.98. In other words for every 100,000 Omeros Corporation shares traded daily on the market, roughly 20980 shares are currently held short.

However Omeros Corporation's short interest can also be evaluated against the total number of Omeros Corporation shares, or, against the total number of tradable Omeros Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Omeros Corporation's short interest could be expressed as 0.16% of the outstanding shares (for every 100,000 Omeros Corporation shares in existence, roughly 160 shares are currently held short) or 0.1649% of the tradable shares (for every 100,000 tradable Omeros Corporation shares, roughly 165 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Omeros Corporation.

Find out more about how you can short Omeros Corporation stock.

Omeros Corporation share dividends

We're not expecting Omeros Corporation to pay a dividend over the next 12 months.

Have Omeros Corporation's shares ever split?

Omeros Corporation's shares were split on 1 October 2009.

Omeros Corporation share price volatility

Over the last 12 months, Omeros Corporation's shares have ranged in value from as little as $5.45 up to $23.14. A popular way to gauge a stock's volatility is its "beta".

OMER.US volatility(beta: 1.17)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Omeros Corporation's is 1.1693. This would suggest that Omeros Corporation's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Omeros Corporation overview

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN), atypical hemolytic uremic syndrome (aHUS), and COVID-19; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consist of PPAR? (OMS405) to treat opioid and nicotine addiction; PDE7 (OMS527) for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.

Frequently asked questions

What percentage of Omeros Corporation is owned by insiders or institutions?
Currently 4.128% of Omeros Corporation shares are held by insiders and 52.272% by institutions.
How many people work for Omeros Corporation?
Latest data suggests 277 work at Omeros Corporation.
When does the fiscal year end for Omeros Corporation?
Omeros Corporation's fiscal year ends in December.
Where is Omeros Corporation based?
Omeros Corporation's address is: The Omeros Building, Seattle, WA, United States, 98119
What is Omeros Corporation's ISIN number?
Omeros Corporation's international securities identification number is: US6821431029
What is Omeros Corporation's CUSIP number?
Omeros Corporation's Committee on Uniform Securities Identification Procedures number is: 682143102

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site